Speakers at the annual general meeting of the Intergovernmental Forum on Mining, Minerals, Metals and Sustainable Development discussed the challenges that faced the mining sector during the virtual event. They also discussed opportunities that would facilitate the transition into a mining sector that was more sustainable and how to achieve the sustainable development goals.
Participants of the forum addressed coronavirus-related loss of employment in the mining community as a result of reduced worker mobility and border closures, as well as safety and health concerns and the increase in food insecurity and poverty. The discussions also covered technological innovation, resource taxation, climate action, artisanal and small-scale mining, gender equality and community resilience.
The main challenges facing the mining sector included:
i. Adoption of tools and approaches for gender-impact assessments. This would help to better understand the potential effect of mining projects in reducing the existing gender-inequality patterns as well as the projects’ effects on indigenous peoples’ territories and ethnic minorities.
ii. Reducing carbon emissions in mining.
iii. Developing policies for mine closure.
iv. Using digital technology to replace physical labor and equipping workers with relevant skills in remote equipment operation, automation and robotics.
v. Improving domestic revenue collection through tax reforms. This would include measures to reduce profit shifting and tax base erosion and advocate for greater transparency in the pricing of minerals.
vi. Maintaining the social license of mining firms to enable them to operate through trust building and accountability.
Forum participants were also introduced to the global campaign, Race to Zero, which strives to achieve net-zero carbon emissions by 2050 through generating leadership and support.
Representatives of the forum presented recommendations on how to improve legal frameworks for management and ESIA (Environmental and Social Impact Assessment). These recommendations sum up the best international practices in this field.
In addition to this, participants also discussed measures to execute the August 2020 Global Industry Standard on Tailings Management. The AGM was a three-day event , with more than 1,800 registered participants from 110 countries globally.
The Intergovernmental Forum, which boasts 76 government members, is the product of the World Summit on Sustainable Development (2002). The summit adopted the Johannesburg Declaration on Sustainable Development, which demanded that the health, economic, environmental and social impacts as well as benefits of mining metals and minerals throughout their life cycle be addressed. The declaration, which focuses on global conditions that pose serious threats to sustainable development, also highlighted worker safety and health issues and promoted accountability and transparency for sustainable mining.
Energy Fuels Inc. (NYSE: American: UUUU) (TSX: EFR) is one interesting company to watch in the mining sector. The company focuses on producing uranium and vanadium, both of which carry the “critical minerals” designation by the U.S. federal government. The company holds the distinction of being the largest uranium producer across the country.
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
Energy Fuels (NYSE American: UUUU) (TSX: EFR) today announced that the company has produced a rare earth element (“REE”) carbonate concentrate (“REE Concentrate”) on a pilot scale at its 100% owned White Mesa Mill (the “Mill”), located near Blanding, Utah. According to the update, the REE Concentrate was produced using the Mill’s existing infrastructure and technologies from a sample of monazite sands from a North American source. A valuable natural uranium ore, monazite sands also contain high concentrations of REEs. The Mill recovered high concentrations of REEs in the monazite sands in addition to the contained uranium, which will be sold into the nuclear fuel industry. The REE Concentrate produced is of high purity and ready to be sent to a separation plant and downstream REE processing facility for final acceptance test work. “This past weekend, Energy Fuels achieved a major milestone in U.S. rare earth element production when we successfully produced a REE Concentrate from a sample of monazite sands at our White Mesa Mill,” Mark S. Chalmers, Energy Fuels’ president and CEO, said in the news release. “Our company literally accomplished REE production in months, because we utilized existing resources, infrastructure and technologies.”
Energy Fuels is a leading U.S.-based uranium mining company, supplying U 3 O 8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant, and is evaluating the potential to also recover rare earth elements at its White Mesa Mill. Its corporate offices are in Lakewood, Colorado near Denver, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) project in Wyoming, and the Alta Mesa ISR project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U 3 O 8 per year, and has the ability to produce vanadium when market conditions warrant. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U 3 O 8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U 3 O 8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” For more information, visit the company’s website at www.EnergyFuels.com.
NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
Sustainable Green Team Ltd. (SGTM) Subsidiary — Mulch Manufacturing — Awarded String of Contracts
Mulch Manufacturing has signed mulch supplier contract with Vero Beach, Florida
This — and other recent contracts — made possible due to SGTM’s recent completion of construction on its Florida Waste Management facility
Sustainable Green Team was created by bringing together three industry-leading companies
Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, has announced that its wholly owned subsidiary will be the official mulch supplier for Vero Beach, Florida (https://ibn.fm/OunIk). Mulch Manufacturing has signed a one-year contract with the Florida city, with two additional one-year extensions.
The Vero Beach contract is the most recent in a string of contracts awarded to Mulch Manufacturing, one of the largest producers of packaged mulch products in the country. Earlier this month, the company obtained mulch contracts from three Circle K convenient store divisions (https://ibn.fm/xBzrT). A week earlier the SGTM subsidiary landed a mulch and soil purchase agreement with the Kroger Co. to provide material for the 94 stories in its Louisville, Kentucky division (https://ibn.fm/s6yJf). And that contract came on the heels of the company being awarded a 2021 mulch packaging contract renewal from Menards Inc. (https://ibn.fm/Ek8QH).
“We are pleased to be awarded this new government contract opportunity,” said SGMT CEO and director Tony Raynor (https://ibn.fm/MTzQp). “And it’s all thanks to our recently completed construction in the Waste Management (‘WM’) facility in central Florida.”
The July 2020 construction at the facility in Apopka, Florida, included a dual line mulch bagger and fully automated electric grinding screen operation. With the new fully electric equipment coming online, the company can increase its mulch production by four million bags per year within one shift. In addition, the new operations will allow full vertical integration at WM’s landfill by utilizing unused debris that is typically buried. Now the unused debris can be reused and branded into a premium mulch product onsite.
“This is a pivotal advancement,” said Raynor commented. “With our strong relationship with Waste Management, we are progressing toward achieving true green sustainability.
Mulch Manufacturing is part of the Sustainable Green Team LTD, which was created by combining the resources of three companies that were leaders In their specialties: Mulch Manufacturing, National Storm Recovery and Central Florida Arbor Care. As a result, SGMT has the expertise to address the needs of each of the combined customers with a new level of quality and cost effectiveness.
The Sustainable Green Team, through its subsidiaries, provides tree services, debris hauling, and removal and bio-mass recycling, as well as manufacturing, packaging and sales of next-generation mulch products. The company’s primary corporate objective is to provide a solution for the treatment and handling of tree debris that is historically sent to local landfills and disposal sites, creating an environmental burden and pressure on disposal sites around the nation.
To learn more about the Sustainable Green Team, view the company’s investor presentation at https://ibn.fm/vLpB2. For more information about Mulch Manufacturing, visit www.MulchMfg.com.
NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Wordson all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
A new study conducted by researchers at the Queen Mary University of London has produced innovative biomarkers that can be used to predict patient responsiveness to DMARDs (disease-modifying anti-rheumatic drugs). Rheumatoid arthritis is an inflammatory disorder that can affect not only one’s joints but also blood vessels, heart, lungs, eyes and skin. The disease causes painful swelling that results in joint deformity and bone erosion.
Patients with rheumatoid arthritis are usually treated using disease-modifying anti-rheumatic drugs. This is despite the fact that almost 50% of rheumatoid arthritis patients are unresponsive to DMARD treatment. Up until now, no method was available to determine if an individual would respond to the treatment effectively.
This new study, published in “Nature Communications,” a science journal, showed that predictions about a patient’s ability to respond to these anti-rheumatic drugs could be made by measuring the levels of specific tiny molecules produced by essential fatty acids in an individuals’ blood. These essential fatty acids usually regulate inflammation and are called specialized pro-resolving mediators.
Professor Jesmond Dalli, the study’s lead author, is from Queen Mary University of London. He has stated that a majority of patients who suffered from rheumatoid arthritis were unresponsive to these anti-rheumatic drugs and were therefore exposed to the drugs’ side effects unnecessarily. Additionally, it takes an average of about six months from initiation of treatment to find out if a patient will or will not respond to these drugs. The disease worsens for patients who do not respond to these drugs before they are able to get a treatment that may work for them.
Dalli explained that the study was carried out using blood samples from healthy rheumatoid arthritis patients who were either unresponsive or responsive to treatment. The samples were collected six months after DMARD treatment began or before initiation of treatment was started. The researchers then used mass spectrometry-based techniques simultaneously with artificial intelligence methods to measure protective molecule levels and also identify molecules that can forecast responses to treatment.
The study recommends that the blood levels of the mediator group, which have been determined in the paper, should be measured. Measuring those blood levers will help forecast the responsiveness of rheumatoid arthritis patients to the disease-modifying anti-rheumatic drug treatment. The team of researchers plans to carry out a larger study to assess their initial findings and find out whether those findings can be applied to a larger patient group.
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is one biomedical company you should watch. The company focuses on developing organ-targeted therapies, especially those for primary and metastatic cancers affecting the central nervous system and the brain.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients with high unmet medical need conditions, today announced that it will host a conference call and live webcast at 5:30 p.m. Eastern Time on Nov. 12, 2020. Topics will include review of the company’s third quarter 2020 results and an update on its clinical pipeline, including discussion of PCSA’s three clinical-stage drugs (each of which addresses potential billion-dollar markets). Interested parties may join the call by dialing 877-876-9176 (Toll Free) or 785-424-1670 (International) and access the live webcast via the following link: https://ibn.fm/vMLlY.
The mission of Processa has been to develop products where existing clinical evidence of efficacy already exists in unmet medical need conditions — medical conditions where patients need treatment options that will improve survival and/or quality of life. The company has assembled a proven regulatory science development team, management team and board of directors. The Processa development team has been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and 100 FDA meetings. For more information, visit the company’s website at www.ProcessaPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at http://ibn.fm/PCSA
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
The functional mushroom space has no clear leader, allowing for Rritual to target the role as the only premium brand currently on the market
The company’s premium suite of products will be available first online through their website and the Amazon shop
Rritual was the runner up for the Buyer’s Choice Award in the virtual ECRM presentation that connects companies with retail establishments creating business relationships
The company was chosen for a special ECRM program on October 22, 2020, due to its award-winning status, connecting it to major retailers such as ALDI, Costco, Albertsons/Safeway, and Amazon
The current functional food market is valued at more than $275 billion
Rritual Mushrooms is a private company that manufactures premium plant-based products including small-batch elixir powders and premium shots made from medicinal mushrooms and adaptogenic herbs.
Rritual’s mission is to help each and every person meet the demands of modern life with style and ease through mushroom adaptogen products, slated to be sold online and through brick and mortar establishments. Through its management team, the company has developed connections with leading retailers and other establishments to begin rolling out its product offering. The first products will be available online through the Rritual website and an exclusive Amazon shop.
Recently, Rritual took part in a virtual program organized by ECRM, an international organization that connects suppliers and buyers. The virtual program, called “The Whole Body and Mind Wellness,” was the first time any ECRM program curated meetings related specifically to wellness lifestyle. Its goal was to connect major retailers with brands that support the growing consumer interest in health and fitness (https://nnw.fm/ScOza).
Rritual was selected as the runner up for the Buyers Choice Award for its Reishi Relax Elixir, picked by retail buyers from dozens of entries. “Retail buyers selected Rritual for the award because our packaging, design and formulation stood out amongst the dozens of products they evaluated,” CEO David Kerbel said. “Their stamp of approval on our product reinforces what we know: that Rritual products will capture the attention of shoppers on shelves and in e-comm, supporting our anticipated year-one growth.”
Due to this award, Rritual was invited to participate in a special ECRM program that took place on October 22, 2020. This event included major retailers such as ALDI, Costco, Albertsons/Safeway, and Amazon.
Rich in polysaccharides, triterpenes, fatty acids, and amino acids, infused with Ashwagandha root to improve sleep quality and promote stress support, Reishi Relax is just one of the products included in Rritual’s premium suite. The other two leading products are Lion’s Mane Focus, paired with Rhodiola root to support cognitive function and overall brain health, and Chaga Immune, full of bioactive polysaccharides and infused with Eleuthero root to create an optimal environment for the body’s immune system.
The company is still in its early development stages, but it has the potential to become the leading force in the functional mushroom and foods market, amid a vacuum of premium brands in the space. The current functional food market is valued at more than $275 billion, with a global shift supporting wellness and the 7.9% CAGR forecast through 2025.
The demand for functional mushrooms is also forecasted to rise from $23 billion to an increase of $34 billion by 2024. Worldwide, the market is expected to reach $50 billion by 2025 due to the popularity of the superfood’s unique properties and the proven abilities to increase cognitive function, boost immunity, and help manage stress.
NOTE TO INVESTORS: The latest news and updates relating to Rritual Mushrooms are available in the company’s newsroom at https://nnw.fm/Rritual
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Wrap Technologies (NASDAQ: WRTC), an innovator of modern policing solutions, announced receipt of new and repeat domestic orders for BolaWrap(R) products and accessories. According to the update, the company has received numerous recent orders from domestic law enforcement agencies and expects to complete shipping next month. In addition, the company today announced the appointment of Jags Gill as its new director of international sales. Based out of London, Gill brings over 15 years of experience in senior sales management across global law enforcement and security sectors. In his new role, Gill will be responsible for managing and driving international sales for WRTC’s products and working closely with president and interim CEO, Tom Smith, to expand the company’s international footprint. “This is our first salesperson living abroad,” Smith said of the appointment. “We are thrilled to have Jags Gill on the team working directly with our international distributors as well as his own direct channels in law enforcement. Jags’ sales and marketing expertise will be a great asset — invaluable as we grow our international business and reputation.”
Wrap Technologies is an innovator of modern policing solutions. The company’s BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar(R) tether to restrain an individual at a range of 10-25 feet. Developed by award winning inventor Elwood Norris, the company’s chief technology officer, the small but powerful BolaWrap 100 assists law enforcement to safely and effectively control encounters, especially those involving an individual experiencing a mental crisis. BolaWrap 100 has already been used to safely apprehend suspects without injury by agencies in cities including Los Angeles, Sacramento, Fresno, Bell, Albuquerque, Minneapolis, West Palm Beach, Fort Worth, LaGrange, St. Cloud and Oak Ridge. For information about the company, please visit www.WrapTechnologies.com.
NOTE TO INVESTORS: The latest news and updates relating to WRTC are available in the company’s newsroom at http://ibn.fm/WRTC
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Study results have exciting therapeutic potential across wide range of CNS indications.
VTGN focused on developing new generation of medications to treat anxiety, depression and more.
Company committed to finding treatment to help estimated 264 million people around the world who suffer from depression.
Noting that 17.3 million adults in the United States have had at least one major depressive episode and some 264 million people around the world suffer from depression, VistaGen Therapeutics (NASDAQ: VTGN) is committed to finding effective treatments for depression that reach beyond the current standard of care, which includes oral antidepressants and oral atypical antipsychotics. The company has released data from a second preclinical study of its oral investigational drug, AV-101, in combination with probenecid. The results, which complement findings from a prior preclinical study, indicate that AV-101, when combined with probenecid, substantially increased the brain concentration of its active metabolite, 7-Cl-KYNA, a potent and selective full antagonist of the N-methyl-D-aspartate receptor (NMDAr) glycine co-agonist site. The combination of drugs may therefore reduce rather than block NMDAr signaling—an effect which could carry significant therapeutic potential.
“These new positive results amplify our message that AV-101, when administered in combination with probenecid, has exciting therapeutic potential across a wide range of CNS (central nervous system) indications,” said VistaGen CEO Shawn Singh. “The studies completed to date are promising and will help us determine the best next step in our overall development plan for the combination.”
VistaGen is assessing the potential of the AV-101/probenecid combination as a treatment for multiple CNS disorders, including dyskinesia (unwanted movement) associated with levodopa therapy for Parkinson’s disease, epilepsy, major depressive disorder, neuropathic pain and suicidal ideation (thoughts and behaviors).The company’s efforts currently are focused on developing three new generation medicines for anxiety, depression and other CNS disorders where the current standard of care is inadequate, resulting in high unmet need. Each of VistaGen’s three drug candidates, AV-101, PH10 and PH94B, has a differentiated mechanism of action, an exceptional safety profile in all studies to date and therapeutic potential in multiple CNS markets.
For more information, visit the company’s website at www.VistaGen.com.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Monday, November 2nd, 2020UncategorizedComments Off on $VTGN Preclinical Study Data Show Drug Combo’s Innovative Potential in Fight Against Major Depressive Disorder
The UK is one of numerous countries that have pledged to phase out internal combustion-powered vehicles in favor of electric vehicles (“EVs”). In summer 2019, then Prime Minister Theresa May signed into law the groundbreaking target of achieving net-zero carbon emissions by 2050. However, one factor that has consistently stood in the way of widespread EV adoption, especially in the less-affluent boroughs of London, is poor charging infrastructure.
To help combat this, global ride-hailing giant Uber Technologies (NYSE: UBER) has pledged to invest more than £5m in public, electric-vehicle charging infrastructure. Uber’s analysis shows that the concentration of public EV chargers is far higher in more affluent boroughs such as Kensington and Westminster compared to boroughs where its drivers typically drive.
The firm also found that compared to residents of southwest London, drivers in boroughs such as Tower Hamlets and Newham were less likely to live in houses with driveways that allow them to charge EVs overnight. Although Uber concedes that the investment is only a fraction of what is needed, it will announce the investment as part of its efforts to highlight the imbalance across the capital in the installation of charging stations.
The £5m in funding will be invested by 2023 in areas that lack the charging infrastructure neededto support electric vehicles, says Uber’s regional general manager Jamie Heywood. Uber is looking to work with the borough councils in Brent, Newham and Tower Hamlets to decide how the funding will be divided up and spent. “Drivers consistently tell us that having reliable, accessible charging near where they live is a key factor when deciding if they should switch to electric,” Heywood says. “If we address this challenge for professional drivers now, it will help create a mass market for electric vehicles in the years to come. As we all know, this is critical if the U is to achieve our goal to be net-zero.”
At the moment, only about 1,000 of the 45,000 vehicles Uber operates in London are electric, a long way from its goal of electrifying its entire London fleet. Still, the firm is making steady progress in achieving that goal.
By charging its customers a clean-air fee at 15% extra per mile, Uber was able to raise more than £100m to help its drivers transition to electric cars. Earlier this year, Uber also struck a deal with Nissan to supply 2,000 discounted Leafs to London drivers.
Net Element (NASDAQ: NETE) is an interesting firm in the EV space that you should watch. The company is in the final stages of completing a merger with Mullen Technologies Inc., a California-based EV company that has been developing, designing and manufacturing lightweight, high-end cars for decades. It will be intriguing to follow how the new entity formed from a financial services company and an automaker pans out.
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Houston-based CNS Pharmaceuticals is preparing to launch Phase 2 clinical testing of a novel brain cancer-fighting drug candidate called Berubicin early next year
The biopharmaceutical company recently announced that a U.S.-based company contracted to make Berubicin has completed its production process and an Italian company working on a dual track in Europe is expected to finish by the end of the year
Berubicin has shown promise in combatting Glioblastoma multiforme, an aggressive form of brain cancer commonly regarded as incurable. One participant in Berubicin’s Phase 1 trial remains cancer-free 14 years after the trial
CNS Pharmaceuticals, with its sublicensee partner WPD Pharmaceuticals, is also preparing for 2 clinical trials in Poland including the first Phase 1 pediatric trial of Berubicin and a parallel Phase 2 trial in adults
The U.S. manufacturer for a novel anthracycline being tested by biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) as a potential new strategy in combatting an inexorable and ultimately fatal type of brain tumor has completed the manufacturing process for the drug candidate, known as Berubicin.
CNS Pharmaceutical engaged Pharmaceutics International, Inc. (“Pii”) to make Berubicin in the United States while BSP Pharmaceuticals S.p.A. (“BSP“) worked on a dual track to make Berubicin in Italy under the company’s strategy of supplying its upcoming Phase 2 trials with sufficient quantities of the orphan drug status product amid the risk of delays in production and shipping as a result of the ongoing COVID-19 pandemic.
Completion of both Pii’s and BSP’s manufacturing of Berubicin moves CNS Pharmaceuticals closer to completing its preparations for filing an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) to fight glioblastoma.
Glioblastoma multiforme (“GBM”) is an aggressive brain cancer that has no known cure, however the Phase 1 trial of Berubicin in 2006 produced some promising results. Of 25 trial participants who were evaluated, 44 percent achieved what the company refers to as “statistically significant improvement in clinical benefit” (https://ibn.fm/tOnAN) while one patient has remained completely cancer-free as of the last evaluation on Feb. 20 — some 14 years after the initial trial phase.
Glioblastoma patients have a median survival rate of only 14.6 months from the date of the malignancy’s diagnosis, although the drug temozolomide has been shown effective in temporarily extending the lifespan of fewer than 40 percent of the GBM patients with a specific genetic variation. The persistent cancer tends to recur after surgery and to develop a resistance to temozolomide over time, making an effective therapy in treating it an attractive goal.
The orphan drug designation grants Berubicin certain benefits during its development and provides CNS with the potential for market exclusivity if the drug is approved for combatting malignant gliomas.
“We are extremely pleased to achieve yet another milestone in our preparation efforts and demonstrate our continued ability to execute upon both our operational and clinical strategies in a timely and proficient manner,” CEO John Climaco stated in the news release. “We remain committed to further progressing our trial preparations, as we look forward to initiating a U.S. Phase 2 trial for Berubicin during the first quarter of 2021.”
As further evidence of the company’s progress toward advancing its clinical testing, CNS has contracted with Worldwide Clinical Trials as the research organization, Image Analysis Group as the imaging partner and with Berry Consultants as a biostatistical adviser for its Phase 2 trial design. CNS has also added renowned neuro-oncologist Dr. Patrick Wen to its Scientific Advisory Board.
For more information, visit the company’s website at www.CNSPharma.com
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, earlier this year announced the closing of a private placement financing (the “offering”). According to the update, AzurRx secured approximately $6.9 million in gross proceeds from certain accredited investors, with Alexander Capital LP acting as sole placement agent in the offering. The company intends to use net proceeds to eliminate short- and long-term indebtedness, as well as for general working capital purposes including product development. “We are very grateful for the continued support of our investors,” James Sapirstein, president and CEO of AzurRx said in the press release. “This financing allows us to achieve our short-term goals and continue the development of our MS1819 program for the treatment of exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis patients.”
AzurRx BioPharma is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819-SD recombinant lipase for exocrine pancreatic insufficiency (“EPI”) is the company’s lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infections. The company is headquartered in Brooklyn, New York, with scientific operations based in Langlade, France. Additional information on the company can be found at www.AzurRx.com.
NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at http://ibn.fm/AZRX
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
A group of researchers associated with various institutions in China has discovered a gut microbe deficiency in children who develop ASD (autism spectrum disorder). This is a developmental disability characterized by stereotyped and repetitive behavior and impaired social communication. In the research, which was published in the “Science Advances” journal, the team of researchers describes their study of gut microbes in autism spectrum disorder children and discusses their findings.
Previous research had suggested that issues with the gut microbiome may be the cause of the development of ASD in the affected children. However, what those issues might be still remains a mystery. In an effort to discover these issues, this research team took a step forward in helping to solve that mystery through their research.
The research involved the collection of stool samples from 40 children who were not on the autism spectrum and an additional 39 subjects who had been diagnosed with ASD. The researchers also took into account the children’s age, the location they lived in and other additional factors.
The reason for identifying gut biome differences is because differences are common between individuals. Each of the stool samples collected underwent metagenomic sequencing. This is the genomic analysis of DNA of microbiota from environmental communities. The purpose of this was to identify whether there is a distinguishable difference between the children who did not have ASD and those who did.
The team of researchers focused primarily on 18 microbiota species that had been linked to autism spectrum disorder in previous research. Doing this helped the team discover differences in the detoxifying enzyme ratios in children with ASD when compared to those of children who do not have ASD. The researchers then tested an additional 65 children who’d been diagnosed with ASD and found the same results.
These findings led the researchers to suggest that autism spectrum disorder may develop in children because the detoxification process in the gut was affected by a compromised gut microbiome. This allowed environmental toxins to enter the bloodstream, where they damaged mitochondria in brain cells, which ultimately led to the development of symptoms related to ASD.
The researchers say that despite the extensive research already done, more work is needed. They suggest that developing a therapy that helps in the detoxification process is possible. This, they say, might help prevent the onset of autism spectrum disorder. The developed therapy may potentially be used to overpower elements that cause the detoxification issues.
Lots of companies are putting the discoveries made about different health conditions to good use. One biomed company you need to watch is AzurRx BioPharma Inc. (NASDAQ: AZRX). AzurRx focuses on using recombinant proteins to develop treatments to address gastrointestinal diseases.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Cybin Corp., a Canada-based, life-science company advancing psychedelic pharmaceuticals, recently announced the appointment of Doug Drysdale as its CEO (https://nnw.fm/wPyaa). Drysdale, named an Ernst and Young Entrepreneur of the Year in 2012, brings more than three decades of experience in the health-care sector and will continue to grow the company’s IP portfolio. “With his myriad of business accomplishments, Doug is the ideal leader for Cybin,” stated Cybin co-founder and COO Paul Glavine of the appointment. “We believe that his extensive health-care sector background and international company management skills will help Cybin strengthen partnerships, develop strategic alliances and expand our international presence. We believe his strong leadership experience will help focus Cybin during our initial path to profitability.”
Cybin is a mushroom life-science company advancing psychedelic and nutraceutical-based products. The company expects to launch psilocybin-based products in jurisdictions where the substance is not prohibited. Simultaneously, the company is structuring and supporting clinical studies across North America and other regions through strategic academic and institutional partnerships. For more information, visit www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://nnw.fm/Cybin
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Knightscope recently named Ms. Mallorie Burak as Executive Vice President and Chief Financial Officer
The company’s autonomous security robots use proprietary technology, combining robotics, self-driving capabilities, and artificial intelligence
Game changing technology has now been in operation over 1 million hours and is operating across 5 time zones 24/7/365
Knightscope is a leader in the development of autonomous security capabilities. The company designs and builds Autonomous Security Robots (“ASRs”), which use Knightscope’s proprietary technology combining robotics, self-driving technologies, and artificial intelligence.
The ASRs have proven to enhance the safety at hospitals, manufacturing plants, logistics facilities, schools, businesses, parking lots, and corporate campuses. This level of versatility enables Knightscope to disrupt the $500 billion security industry by offering reliable and cost-effective security solutions for a wide range of scenarios and locations – even during a pandemic. Knightscope currently has three models on the market, with one currently in long-term development – which all drive over 90 terabytes a year of data per machine to an intuitive browser-based user interface.
K1 ASR – The K1 ASR is the 2018 Security Today New Product of the Year award winner. The K1 is a stationary indoor/outdoor unit that can be put in high-risk areas, lobby and reception areas, and parking lots. The K1 runs 24/7 and can be used at help and assistance points using the two-way intercom feature.
K3 ASR – The K3 is an autonomously recharging indoor patrol ASR. The K3 is fully integrated with the Knightscope Security Operations Center (“KSOC”). Which makes it the smart eyes and ears of malls, warehouses, hospitals, offices, and several other locations where indoor patrol is optimal.
K5 ASR – Primarily used outdoors, the K5 features the KSOC technology and autonomously recharges itself as well. It has been in operation for over 1 million hours and worked through its third winter, and still going strong.
K7 ASR – The K7 is the latest ASR under development. This ASR is planned to handle rougher terrain, making it great for airports, utilities, federal government facilities, and many others. The ASR is also planned to be fully integrated with the KSOC user interface technology.
KSOC – the Knightscope Security Operations Center (“KSOC”) is the browser-based user interface our clients utilize to have the magic of our technology at their fingertips.
Providing real-time access to data around the clock, KSOC also features 360-degree eye-level HD video streaming, people detection, facial recognition, automatic license plate recognition, thermal anomaly detection, and automatic signal detection. The technology is also available to schedule patrols, maintain autonomous charging, analytics, live audio broadcast, two-way intercom, pre-recorded broadcast messages, and the capability to conduct investigations as well as obtain court admissible evidence.
Since Knightscope’s inception, it has raised over $70 million with over 16,000 investors. In preparation for a potential public listing, the company is in the process of raising an additional $25 million. It has already reserved the NASDAQ ticker symbol “KSCP.”
The company recently appointed Ms. Mallorie Burak as Executive Vice President and Chief Financial Officer. Ms. Burak is an experienced financial executive with over 25 years of expertise in many industries that range from early-stage start-ups to multi-national corporations. Ms. Burak’s previous experience includes CFO for ThinFilms Electronics ASA and many other industry leaders in which she held the CFO title. She has a proven track record of creating a high-performing culture with a focus on operational excellence (https://nnw.fm/hYuei).
Knightscope’s core mission is to make the United States of America the safest nation in the world. Through its innovative, proprietary technology, the company plans on supporting the millions of law enforcement and security professionals across the country.
NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://nnw.fm/Knight
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Monday, November 2nd, 2020UncategorizedComments Off on Knightscope, Inc. Creating Change in the Security Industry Through Proprietary Technology to Assist Law Enforcement and Private Security
